Early Response to MASH Drug Linked to Resolution, Fibrosis Improvement
(MedPage Today) -- In patients treated with resmetirom (Rezdiffra), early responses in blood and imaging biomarkers were associated with resolution of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis improvement, according to...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.